Close Menu

Pacific Biosciences

The GenomeWeb Index stayed relatively flat in November, underperforming the Dow and Nasdaq for a second month in a row.

Roche said the timeline to launch a diagnostic system and assays based on PacBio's technology would be too long; instead, it will focus on commercializing Genia's technology.

The two companies struck a $75 million deal in 2013 to launch a sequencing system and assays for the diagnostic market. 

The GenomeWeb Index, which fell nearly 9 percent in October, rebounded to a 1 percent gain in November, but still underperformed the Dow and Nasdaq.

PacBio released an upgrade to its Sequel system last month that improves loading efficiency, which has increased average throughput and read length. 

PacBio's product revenues increased due to sales of its Sequel system. The company also alleged that Oxford Nanopore's products infringe on a patent it holds. 

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Researchers from Pacific Biosciences and elsewhere tested their approach on Arabidopsis thaliana before applying it to wine grape and coral fungus genomes.

The researchers believe using PacBio's Sequel systems will allow them to create high-quality reference genome assemblies.

The researchers have generated the most contiguous de novo assembly of a human genome to date and plan to use it as a reference for population sequencing projects.

Pages

CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.

Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.

Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.

In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.